Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Mallinckrodt
Medtronic
Boehringer Ingelheim
AstraZeneca

Last Updated: September 30, 2022

Teva Pharm Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Teva Pharm

Drugs and US Patents for Teva Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa BUDESONIDE budesonide SUSPENSION;INHALATION 204548-001 Mar 8, 2016 AN RX No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa IMATINIB MESYLATE imatinib mesylate TABLET;ORAL 204285-001 Aug 4, 2016 AB RX No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa CYTOSAR-U cytarabine INJECTABLE;INJECTION 075206-001 Dec 30, 1998 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Pharms DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 040472-004 Sep 30, 2003 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa POMALIDOMIDE pomalidomide CAPSULE;ORAL 209956-004 May 4, 2022 AB RX No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Teva Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 6,939,539 See Plans and Pricing
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 7,842,687 See Plans and Pricing
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-002 Jan 27, 2017 6,446,627 See Plans and Pricing
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-005 Jul 12, 2019 8,006,690 See Plans and Pricing
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-005 Feb 20, 2020 6,871,646 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TEVA PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 2016-10-26
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-01-29
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 2008-08-11
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-02-26
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
Premature patent expirations for TEVA PHARM

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
See Plans and Pricing See Plans and Pricing

Supplementary Protection Certificates for Teva Pharm Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2785706 2020C/516 Belgium See Plans and Pricing PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318
2443246 39/2021 Austria See Plans and Pricing PRODUCT NAME: ICOSAPENT-ETHYL (= EICOSAPENTAENSAEUREETHYLESTER,; REGISTRATION NO/DATE: EU/1/20/1524 20210329
2506844 LUC00077 Luxembourg See Plans and Pricing PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1304992 C01304992/01 Switzerland See Plans and Pricing PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
1663240 93382 Luxembourg See Plans and Pricing PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE ET TENOFOVIR ALAFENAMIDE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE DE TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/16/1112 ODEFSEY - EMTRICITABINE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Harvard Business School
Johnson and Johnson
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.